The PI3K/AKT/mTOR Signaling Pathway Is Overactivated in Primary Aldosteronism

被引:41
|
作者
Su, Hengchuan [1 ]
Gu, Yanyun [2 ]
Li, Fengying [2 ]
Wang, Qidi [2 ]
Huang, Baoxing [1 ]
Jin, Xiaolong [3 ]
Ning, Guang [2 ]
Sun, Fukang [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Urol, Shanghai 200030, Peoples R China
[2] Shanghai Jiao Tong Univ, Dept Endocrinol, Clin Ctr Shanghai Endocrine & Metab Dis, Ruijin Hosp,Sch Med, Shanghai 200030, Peoples R China
[3] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Pathol, Shanghai 200030, Peoples R China
来源
PLOS ONE | 2013年 / 8卷 / 04期
关键词
MTOR PATHWAY; DIAGNOSIS; APOPTOSIS; INCREASES; SECRETION; CANCER; FORMS;
D O I
10.1371/journal.pone.0062399
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: To date, the available non-invasive remedies for primary aldosteronism are not satisfactory in clinical practice. The phosphoinositide 3-kinase (PI3Ks)/protein kinase B (PKB or AKT)/mammalian target of rapamycin (mTOR) signaling pathway is essential for tumorigenesis and metastasis in many types of human tumors, including renal cancer, adrenal carcinoma and pheochromocytoma. The possibility that this pathway is also necessary for the pathogenesis of primary aldosteronism has not yet been explored. To answer this question, we investigated the activity of the PI3K/AKT/mTOR signaling pathway in normal adrenal glands (NAGs), primary aldosteronism (PA) patients and NCI-H295R cells. Methodology/Principal Findings: Between January 2005 and December 2011, we retrospectively reviewed the records of 45 patients with PA. We compared clinical characteristics (age, gender and biochemical data) and the expression of phospho-AKT (p-AKT), phospho-mTOR (p-mTOR), phospho-S6 (p-S6) and vascular endothelial growth factor (VEGF) by immunohistochemical staining and western blotting, analyzing 30 aldosterone-producing adenomas (APAs), 15 idiopathic hyperaldosteronism (IHA) tissues and 12 NAGs following nephrectomy for renal tumors (control group). Compared with the control group, most of the PA patients presented with polydipsia, polyuria, resistant hypertension, profound hypokalemia, hyperaldosteronemia and decreased plasma renin activity. Compared with normal zona glomerulosa, the levels of p-AKT, p-mTOR, p-S6 and VEGF were significantly upregulated in APA and IHA. No significant differences were found between APA and IHA in the expression of these proteins. Additionally, positive correlations existed between the plasma aldosterone levels and the expression of p-AKT and p-mTOR. In vitro studies showed that mTOR inhibitor rapamycin could inhibit cell proliferation in NCI-H295R cells in a dose-and time-dependent manner. Furthermore, this inhibitor also decreased aldosterone secretion. Conclusions: Our data suggest that the PI3K/AKT/mTOR signaling pathway, which was overactivated in APA and IHA compared with normal zona glomerulosa, may mediate aldosterone hypersecretion and participate in the development of PA.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] The PI3K/Akt/mTOR signaling pathway
    Dennis, P. A.
    ANNALS OF ONCOLOGY, 2011, 22 : 19 - 19
  • [2] RAS Signaling in the PI3K/AKT/MTOR Pathway
    Nussinov, Ruth
    Zhang, Mingzhen
    Jang, Hyunbum
    BIOPHYSICAL JOURNAL, 2020, 118 (03) : 51A - 51A
  • [3] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
  • [4] Stability Analysis of the PI3K–Akt–mTOR Signaling Pathway
    Sapega T.S.
    Guria G.T.
    Biophysics, 2020, 65 (2) : 259 - 267
  • [5] AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
    Bhatt, Aadra P.
    Damania, Blossom
    FRONTIERS IN IMMUNOLOGY, 2013, 3
  • [6] Targeting the PI3K/AKT/mTOR Signaling Pathway in Medulloblastoma
    Dimitrova, V.
    Arcaro, A.
    CURRENT MOLECULAR MEDICINE, 2015, 15 (01) : 82 - 93
  • [7] PI3K/AKT/mTOR Signaling Pathway Is Required for JCPyV Infection in Primary Astrocytes
    Wilczek, Michael P.
    Armstrong, Francesca J.
    Mayberry, Colleen L.
    King, Benjamin L.
    Maginnis, Melissa S.
    CELLS, 2021, 10 (11)
  • [8] Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
    Li, Huayi
    Prever, Lorenzo
    Hirsch, Emilio
    Gulluni, Federico
    CANCERS, 2021, 13 (14)
  • [9] PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
    Li, Xiaoman
    Wu, Changjing
    Chen, Nianci
    Gu, Huadi
    Yen, Allen
    Cao, Liu
    Wang, Enhua
    Wang, Liang
    ONCOTARGET, 2016, 7 (22) : 33440 - 33450
  • [10] Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors
    Welker, Mark E.
    Kulik, George
    BIOORGANIC & MEDICINAL CHEMISTRY, 2013, 21 (14) : 4063 - 4091